<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04481256</url>
  </required_header>
  <id_info>
    <org_study_id>73750</org_study_id>
    <nct_id>NCT04481256</nct_id>
  </id_info>
  <brief_title>TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY</brief_title>
  <acronym>TAPESTRY</acronym>
  <official_title>TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catharina Ziekenhuis Eindhoven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Verbeeten Insituut Tilburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Elisabeth-TweeSteden Ziekenhuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radiotherapeutic Institute Friesland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medisch Centrum Leeuwarden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radiotherapy Group Deventer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Deventer Ziekenhuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rijnstate Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastro Clinic, The Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zuyderland Medisch Centrum</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Isala</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ZGT</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the feasibility of treatment with bintrafusp&#xD;
      alfa combined with definitive chemoradiation (carboplatin, paclitaxel and radiation) in&#xD;
      patients with squamous cell carcinoma of the esophagus or gastroesophageal junction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-randomized feasibility study with paclitaxel, carboplatin, bintrafusp alfa, and&#xD;
      radiation. Paclitaxel 50 mg/m2 and carboplatin AUC = 2 will be given intravenously (i.v.) on&#xD;
      days 1, 8, 15, 22, 29 and 36. Bintrafusp alfa will be given i.v. every three weeks on day 1,&#xD;
      22, and 43 at a dose of 2400 mg. External beam radiotherapy will be delivered to a total dose&#xD;
      of 50.4 Gy in 28 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the&#xD;
      first cycle of chemotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 11, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Non-randomized feasibility study with paclitaxel, carboplatin, bintrafusp alfa, and radiation. Paclitaxel 50 mg/m2 and carboplatin AUC = 2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36. Bintrafusp alfa will be given i.v. every three weeks on day 1, 22, and 43 at a dose of 2400 mg. External beam radiotherapy will be delivered to a total dose of 50.4 Gy in 28 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility difined as the percentage of patients completing at least two cycles of bintrafusp alfa</measure>
    <time_frame>36 months</time_frame>
    <description>The primary outcome of this study is the percentage of patients that completes at least two cycles of bintrafusp alfa together with their chemoradiotherapy regimen.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of toxicity</measure>
    <time_frame>36 months</time_frame>
    <description>Incidence and severity of toxicity defined according to CTCAE v5 and and Radiation Oncology Group (RTOG) criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage completion</measure>
    <time_frame>36 months</time_frame>
    <description>Percentage completion of chemotherapy and radiation treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage withdrawal rate</measure>
    <time_frame>36 months</time_frame>
    <description>Percentage withdrawal rate from chemoradiation due to bintrafusp alfa related complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>locoregional progression</measure>
    <time_frame>36 months</time_frame>
    <description>Infield locoregional progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression</measure>
    <time_frame>36 months</time_frame>
    <description>Any progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>36 months</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ C30))</measure>
    <time_frame>36 months</time_frame>
    <description>Overall Quality of life ranging from 0-100 with 100 being best Quality of Life with special focus on dysphagia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>36 months</time_frame>
    <description>To determine the number and grade of adverse events of bintrafusp alfa combined with chemoradiotherapy according to NCI common toxicity criteria (CTC) version 5</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Biomarker</measure>
    <time_frame>54 months</time_frame>
    <description>To perform exploratory biomarker analyses for treatment response</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">49</enrollment>
  <condition>Carcinoma, Squamous Cell</condition>
  <condition>Oesophageal Cancer</condition>
  <arm_group>
    <arm_group_label>1 Bintrafusp alfa, Paclitaxal, Carboplatin, Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-randomized feasibility study with paclitaxel, carboplatin, bintrafusp alfa, and radiation. Paclitaxel 50 mg/m2 and carboplatin AUC = 2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36. Bintrafusp alfa will be given i.v. every three weeks on day 1, 22, and 43 at a dose of 2400 mg.&#xD;
External beam radiotherapy will be delivered to a total dose of 50.4 Gy in 28 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External beam radiotherapy</intervention_name>
    <description>External beam radiotherapy will be delivered to a total dose of 50.4 Gy in 28 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy</description>
    <arm_group_label>1 Bintrafusp alfa, Paclitaxal, Carboplatin, Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bintrafusp alfa</intervention_name>
    <description>Bintrafusp alfa will be given i.v. every three weeks on day 1, 22, and 43 at a dose of 2400 mg.</description>
    <arm_group_label>1 Bintrafusp alfa, Paclitaxal, Carboplatin, Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel 50 mg/m2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36.</description>
    <arm_group_label>1 Bintrafusp alfa, Paclitaxal, Carboplatin, Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin AUC = 2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36.</description>
    <arm_group_label>1 Bintrafusp alfa, Paclitaxal, Carboplatin, Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven squamous cell carcinoma of the esophagus or gastro esophageal&#xD;
             junction.&#xD;
&#xD;
          -  Surgically irresectable (T1-T4a, N0 or N+, M0), as determined by Endoscopic Ultra&#xD;
             Sound (EUS), PET scan and diagnostic CT scan of neck, thorax and abdomen. Patients&#xD;
             with M1 disease solely on the basis of supraclavicular metastasis are eligible.&#xD;
             Patients with resectable tumors refusing radical surgery are eligible.&#xD;
&#xD;
          -  Locoregional recurrences without distant metastasis after surgery alone or&#xD;
             endoscopical resection&#xD;
&#xD;
          -  Locoregional recurrences without distant metastasis after neoadjuvant chemoradiation +&#xD;
             resection or definitive chemoradiation outside the previously irradiated area,&#xD;
             provided that full dose of radiation can safely be delivered.&#xD;
&#xD;
          -  Tumors that cannot be passed with an endoscope for endoscopic ultrasound are eligible&#xD;
             if all other criteria are fulfilled.&#xD;
&#xD;
          -  If the tumor extends below the gastroesophageal (GE) junction into the proximal&#xD;
             stomach, the bulk of the tumor must involve the esophagus or GE junction.&#xD;
&#xD;
          -  Age ≥ 18.&#xD;
&#xD;
          -  ECOG performance status 0-2 (cf. Appendix A).&#xD;
&#xD;
          -  Adequate hematological, renal and hepatic functions defined as:&#xD;
&#xD;
               -  Neutrophils ≥ 1.5 x 109/L&#xD;
&#xD;
               -  Platelets ≥ 100 x 109/L&#xD;
&#xD;
               -  Hemoglobin ≥ 5.6 mmol&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 x upper normal limit&#xD;
&#xD;
               -  ASAT and ALAT ≤ 1.5 x upper normal limit, Alkaline Phosphatase ≤ 2.5 x upper&#xD;
                  normal limit.&#xD;
&#xD;
               -  PT (INR) ≤ 1.5 x upper normal limit and aPTT ≤ 1.5 x upper normal limit.&#xD;
&#xD;
               -  Creatinine clearance (Cockroft) &gt; 60 ml/min&#xD;
&#xD;
          -  Written, voluntary informed consent&#xD;
&#xD;
          -  Patients must be accessible to management and follow-up in the treatment center&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Past or current history of malignancy other than entry diagnosis interfering with&#xD;
             prognosis of esophageal cancer.&#xD;
&#xD;
          -  Patient with tracheo-esophageal fistula or extension into the mucosal layer of the&#xD;
             trachea, highly at risk to develop fistula. Thus, tumor extension to the trachea is&#xD;
             allowed, but not through the trachea.&#xD;
&#xD;
          -  Patients with pathological lymph nodes at both supraclavicular and truncus coeliacus&#xD;
             level.&#xD;
&#xD;
          -  Pregnancy (positive serum pregnancy test), planning to become pregnant, and lactation.&#xD;
&#xD;
          -  Patient (male or female) in the reproductive age is not willing to use highly&#xD;
             effective methods of contraception (per institutional standard) during treatment and&#xD;
             for 6 months (male or female) after the end of treatment.&#xD;
&#xD;
          -  Previous chemotherapy, radiation and/or treatment with checkpoint inhibitors for the&#xD;
             currently present esophageal tumor.&#xD;
&#xD;
          -  Previous chemotherapy and/or treatment with targeted agents and/or checkpoint&#xD;
             inhibitors for other forms of cancer within the last six months.&#xD;
&#xD;
          -  Previous radiation to the mediastinum precluding full dose radiation of the currently&#xD;
             present esophageal tumor.&#xD;
&#xD;
          -  Persisting grade &gt;1 NCI CTCAE 5.0 toxicity (except alopecia and vitiligo) related to&#xD;
             prior therapy; however, grade ≤2 sensory neuropathy is acceptable.&#xD;
&#xD;
          -  Presence of an esophageal stent.&#xD;
&#xD;
          -  History of bleeding diathesis or major bleeding event (grade ≥ 2) in the month prior&#xD;
             to first dose of trial treatment.&#xD;
&#xD;
          -  Clinically significant cardiovascular disease precluding safe treatment with&#xD;
             chemoradiation.&#xD;
&#xD;
          -  Evidence of pulmonary fibrosis and/or clinically significant impairment of lung&#xD;
             function precluding safe treatment with chemoradiation. In case of doubt about&#xD;
             pulmonary function, a lung function test should be performed and, in case of&#xD;
             abnormalities, discussed with the principle investigator.&#xD;
&#xD;
          -  Serious underlying medical condition which would impair the ability of the patient to&#xD;
             receive the planned treatment, including prior allergic reactions to drugs containing&#xD;
             cremophor, such as teniposide or cyclosporine.&#xD;
&#xD;
          -  Mental status that would prohibit the understanding and giving of informed consent.&#xD;
&#xD;
          -  Inadequate caloric- and/or fluid intake despite consultation of a dietician and/or&#xD;
             tube feeding.&#xD;
&#xD;
          -  Has an active autoimmune disease that has required systemic treatment in past 2 years&#xD;
             (i.e. with use of disease modifying agents, corticosteroids, or immunosuppressive&#xD;
             drugs). Replacement therapy (e.g., thyroxine for patients with a history of&#xD;
             autoimmune-related hypothyroidism, insulin for patients with type 1 diabetes mellitus,&#xD;
             or physiologic corticosteroid replacement therapy for adrenal or pituitary&#xD;
             insufficiency, etc.) is not considered a form of systemic treatment. Patients with&#xD;
             vitiligo with dermatological manifestations only are eligible to enter the study.&#xD;
&#xD;
          -  A diagnosis of immunodeficiency or is receiving systemic steroid therapy (&gt;10 mg/day&#xD;
             prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days&#xD;
             prior to the first dose of trial treatment.&#xD;
&#xD;
          -  Diagnosis of HIV unless stable on antiretroviral therapy for at least 4 weeks, no&#xD;
             evidence of multi-drug resistance, viral load of &lt; 400 copies/ml and CD4+ T-cells ≥&#xD;
             350 cells/µl.&#xD;
&#xD;
          -  Active HBV/HCV. Participants on a stable dose of antiviral therapy with HBV/HCV viral&#xD;
             load below the limit of quantification are eligible.&#xD;
&#xD;
          -  Evidence of interstitial lung disease or active, non-infectious pneumonitis.&#xD;
&#xD;
          -  An active infection requiring systemic therapy, which has not resolved 3 days (simple&#xD;
             infection such as cystitis) to 7 days (severe infection such as pyelonephritis) prior&#xD;
             to the first dose of trial treatment.&#xD;
&#xD;
          -  Administration of a live vaccine within 30 days prior to the first dose of trial&#xD;
             treatment. Seasonal flu vaccines that do not contain a live virus are permitted.&#xD;
&#xD;
          -  Patients with prior allogeneic stem cell or solid organ transplantation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanneke WM van Laarhoven, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Linde Veen</last_name>
    <phone>020-5665955</phone>
    <email>l.veen1@amsterdamumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hanneke WM van Laarhoven, MD, PhD</last_name>
    <phone>020-5665955</phone>
    <email>h.vanlaarhoven@amsterdamumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Academic Medical Center, Medical Oncology</name>
      <address>
        <city>Amsterdam</city>
        <zip>1100 DD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H WM van Laarhoven, MD, PhD, PhD</last_name>
      <phone>31 20 5665955</phone>
      <email>h.vanlaarhoven@amc.uva.nl</email>
    </contact>
    <contact_backup>
      <last_name>Lyda ter Hofstede</last_name>
      <phone>31 20 5668229</phone>
      <email>trialmedonc@amc.uva.nl</email>
    </contact_backup>
    <investigator>
      <last_name>H. WM van Laarhoven, MD, PhD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 26, 2020</study_first_submitted>
  <study_first_submitted_qc>July 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2020</study_first_posted>
  <last_update_submitted>January 15, 2021</last_update_submitted>
  <last_update_submitted_qc>January 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>H.W.M. van Laarhoven</investigator_full_name>
    <investigator_title>Prof. dr.</investigator_title>
  </responsible_party>
  <keyword>Definitive chemoradiation</keyword>
  <keyword>TGF-beta inhibition</keyword>
  <keyword>PDL-1 ihibition</keyword>
  <keyword>feasability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

